Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2023)

Historic Accumulated Expenses for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $20.9 million.

  • Cullinan Therapeutics' Accumulated Expenses rose 5507.51% to $20.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $20.9 million, marking a year-over-year increase of 5507.51%. This contributed to the annual value of $14.1 million for FY2022, which is 6480.12% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Accumulated Expenses stood at $20.9 million for Q3 2023, which was up 5507.51% from $15.5 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Accumulated Expenses ranged from a high of $20.9 million in Q3 2023 and a low of $4.2 million during Q2 2021
  • Moreover, its 4-year median value for Accumulated Expenses was $11.2 million (2022), whereas its average is $11.2 million.
  • As far as peak fluctuations go, Cullinan Therapeutics' Accumulated Expenses soared by 18114.81% in 2022, and later skyrocketed by 3050.16% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Accumulated Expenses (Quarter) stood at $4.6 million in 2020, then surged by 84.81% to $8.6 million in 2021, then soared by 64.8% to $14.1 million in 2022, then surged by 48.19% to $20.9 million in 2023.
  • Its Accumulated Expenses stands at $20.9 million for Q3 2023, versus $15.5 million for Q2 2023 and $18.4 million for Q1 2023.